Lung cancer is the most common cause of cancer-related death in the world. Recently, better understanding of the biology of lung cancer has led to the development of newer targeted therapies for specific subpopulations of lung cancer patients. While this has led to multiple exciting advances that promise to improve outcomes in the future, there has also been a significant increase in the complexity of care of the lung cancer patient. Part of the Oxford American Oncology Library, this concise handbook identifies best-practice guidelines, as well as differences of opinion in the field. It...

While patients with metastatic renal cell carcinoma (mRCC) are now living longer with improved quality of life, the success of novel therapies for mRCC has created challenges for practicing oncologists. Many patients who initially respond to targeted therapies ultimately develop progressive disease due to acquired resistance to these agents. Additionally, some patients do not respond at all to any of the currently approved targeted agents, underscoring the need for continued and concerted efforts to identify other relevant targets and pursue alternative therapeutic strategies. Part of the...